FHIP1A-DT是通过分歧转录获得的一种长非编码RNA（lncRNA），其在泛癌和结直肠癌（CRC）中的作用机制尚不清楚。我们通过生物信息学分析和体外实验阐明了FHIP1A-DT的分子机制。我们从加州大学圣克鲁兹（UCSC）基因组浏览器和癌症基因组图谱（TCGA）下载了泛癌和CRC数据。我们分析了FHIP1A-DT的表达及其与泛癌临床分期、诊断、预后和免疫特性的关系。我们还分析了CRC中FHIP1A-DT的表达，并探讨了FHIP1A-DT与CRC诊断和预后之间的关系。然后，我们分析了FHIP1A-DT与药物敏感性、免疫细胞浸润以及涉及FHIP1A-DT的生物过程之间的相关性。我们还探索了与FHIP1A-DT相关的竞争性内源RNA（ceRNA）调控网络。我们使用外部数据集GSE17538和GSE39582以及体外实验进行了外部验证。FHIP1A-DT在泛癌中的表达不同，并具有出色的泛癌诊断和预后能力。FHIP1A-DT还与泛癌肿瘤突变负荷（TMB），微卫星不稳定性（MSI）和免疫细胞含量相关。FHIP1A-DT在CRC中呈下调状态，CRC患者低FHIP1A-DT表达与更糟预后相关。结合FHIP1A-DT表达的名词图展示了优秀的预后预测能力。基因本体论（GO）和京都基因和基因组百科全书（KEGG）分析表明，FHIP1A-DT与表观遗传修饰有关并调控了许多与癌症相关的途径。ceRNA网络展示了FHIP1A-DT的潜在基因调控。FHIP1A-DT与多种化疗药物敏感性和免疫细胞浸润相关，如CD4记忆静止T细胞、单核细胞、浆细胞、中性粒细胞和M2巨噬细胞。GSE17538和GSE39582的FHIP1A-DT表达和预后分析以及qPCR得出了类似的外部验证结果。FHIP1A-DT是一种新型与CRC诊断、预后和治疗敏感性相关的CRC相关lncRNA。在未来，它可以作为重要的CRC生物标志物。 ©2023年 作者。由Elsevier公司出版。保留所有权利。

FHIP1A-DT is a long non-coding RNA (lncRNA) obtained by divergent transcription whose mechanism in pan-cancer and colorectal cancer (CRC) is unclear. We elucidated the molecular mechanism of FHIP1A-DT through bioinformatics analysis and in vitro experiments.Pan-cancer and CRC data were downloaded from the University of California, Santa Cruz (UCSC) Genome Browser and the Cancer Genome Atlas (TCGA). We analyzed FHIP1A-DT expression and its relationship with clinical stage, diagnosis, prognosis, and immunity characteristics in pan-cancer. We also analyzed FHIP1A-DT expression in CRC and explored the relationship between FHIP1A-DT and CRC diagnosis and prognosis. Then, we analyzed the correlation between FHIP1A-DT and drug sensitivity, immune cell infiltration, and the biological processes involved in FHIP1A-DT. The competing endogenous RNA (ceRNA) regulatory network associated with FHIP1A-DT was explored. External validation was conducted using external data sets GSE17538 and GSE39582 and in vitro experiments.FHIP1A-DT expression was different in pan-cancer and had excellent diagnostic and prognostic capability for pan-cancer. FHIP1A-DT was also related to the pan-cancer tumor mutation burden (TMB), microsatellite instability (MSI), and immune cell content. FHIP1A-DT was downregulated in CRC, where patients with CRC with low FHIP1A-DT expression had a worse prognosis. A nomogram combined with FHIP1A-DT expression demonstrated excellent predictive ability for prognosis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses indicated that FHIP1A-DT was associated with epigenetic modification and regulated many cancer-related pathways. The ceRNA network demonstrated the potential gene regulation of FHIP1A-DT. FHIP1A-DT was related to many chemotherapeutic drug sensitivities and immune cell infiltration such as CD4 memory resting T cells, monocytes, plasma cells, neutrophils, and M2 macrophages. The FHIP1A-DT expression and prognostic analysis of GSE17538 and GSE39582, and qPCR yielded similar external verification results.FHIP1A-DT was a novel CRC-related lncRNA related to CRC diagnosis, prognosis, and treatment sensitivity. It could be used as a significant CRC biomarker in the future.Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.